HER2

Anti-tumor activity of dendritic cell-cytokine induced killer cells (DC-CIKs) sensitized to HER2 against HER-positive breast cancer cells

Y. Y. Wen, Hu, X. S., Wen, Y. Y., Hu, X. S., Wen, Y. Y., and Hu, X. S., Anti-tumor activity of dendritic cell-cytokine induced killer cells (DC-CIKs) sensitized to HER2 against HER-positive breast cancer cells, vol. 15, p. -, 2016.

This study aimed to investigate the cytotoxicity of cytokine-induced killer cells (CIKs) and Her2 epitope peptide-sensitized dendritic cells (DCs), when co-cultured with Her2-positive MCF-7 cells. DCs were separated from the Her epitope peptide-sensitized peripheral blood; the Her epitope combines directly with the MHC-II molecule on the DC surface. The DCs were co-cultured with autologous CIKs.

Preoperative chemotherapy with a trastuzumab-containing regimen for a patient with gastric cancer and hepatic metastases

Z. - Y. Li, Shan, F., Zhang, L. - H., Bu, Z. - D., Wu, A. - W., Wu, X. - J., Zong, X. - L., Li, S. - X., Ji, X., and Ji, J. - F., Preoperative chemotherapy with a trastuzumab-containing regimen for a patient with gastric cancer and hepatic metastases, vol. 13, pp. 10952-10957, 2014.

Gastric cancer is the fourth most common cancer worldwide and the leading cause of tumor-related death in China. Gastric cancer is a heterogeneous disease and therefore requires different treatments based on the subtype. We describe a patient who had gastric cancer with liver metastases. Biopsy and tumor analysis using the HercepTest revealed a human epidermal growth factor receptor 2 (HER2)-positive adenocarcinoma as confirmed by fluorescence in situ hybridization. The patient was treated with a regimen of trastuzumab, oxaliplatin, and S-1 (six cycles).

Subscribe to HER2